All Stories

Boston Scientific’s TAVR hopes dashed again, as it pulls Acurate heart valves from global market

It’s yet another setback for the company’s plans to break into the TAVR market, after it shuttered its Lotus Edge program in late 2020.

May 28, 2025 - 16:10
 0
Boston Scientific’s TAVR hopes dashed again, as it pulls Acurate heart valves from global market
It’s yet another setback for the company’s plans to break into the TAVR market, after it shuttered its Lotus Edge program in late 2020.
Read More

Tags:

Previous Article

InflaRx drops rare skin disease study for COVID med vilobelimab after futility s...

Next Article

GSK-licensed antibiotic meets goal in late-stage study

Related Posts

Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact

Eli Lilly strengthens RNA pipeline with $1.3B biobucks ...

May 16, 2025  0

Fierce Biotech Layoff Tracker 2025: iTeos winds down; Boundless lets go of 33% of staffers

Fierce Biotech Layoff Tracker 2025: iTeos winds down; B...

May 28, 2025  0

BioNTech pledges £1B to bolster UK presence while nabbing £129M grant from government

BioNTech pledges £1B to bolster UK presence while nabbi...

May 20, 2025  0